American Journal of Cancer Prevention
ISSN (Print): 2328-7314 ISSN (Online): 2328-7322 Website: http://www.sciepub.com/journal/ajcp Editor-in-chief: Nabil Abdel-Hamid
Open Access
Journal Browser
Go
American Journal of Cancer Prevention. 2015, 3(3), 58-61
DOI: 10.12691/ajcp-3-3-3
Open AccessResearch Article

Expression of p53 and Ki67 in the Patients with Triple Negative Breast Cancer and Invasive Ductal Carcinoma

Mehrdad Payandeh1, Reza Malayeri2, Masoud Sadeghi3, 4, , Edris Sadeghi3, 4 and Faezeh Gholami3

1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Breast Cancer Research Center, Tehran, Iran

3Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

4Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Pub. Date: May 31, 2015
(This article belongs to the Special Issue Advances in Breast Cancer)

Cite this paper:
Mehrdad Payandeh, Reza Malayeri, Masoud Sadeghi, Edris Sadeghi and Faezeh Gholami. Expression of p53 and Ki67 in the Patients with Triple Negative Breast Cancer and Invasive Ductal Carcinoma. American Journal of Cancer Prevention. 2015; 3(3):58-61. doi: 10.12691/ajcp-3-3-3

Abstract

Background: Breast cancer is the most common cancer (27% of all cancers) and common cause of death (16%) which occurs due to cancers among women, either in developed or developing. The aim of study is to evaluated clinicopathology figures especially Tumor markers such as Ki6 and p53 in the patients with TNBC. Materials and Methods: Between of 2005 to 2014, 50 patients with triple negative breast cancer and invasive ductal carcinoma referred to our Clinic. Age, sex, metastasis, Ki67, p53, laterality, treatment options and The OS were checked in the patients. Results: The mean age for the patients at diagnosis was 51.04, 100% female. We divided the patients based on Ki67 to two groups, 24 patients (48%) with low Ki67 (<10%) and 26 patients (52%) with high Ki67 (≥10%). Also, Seventeen patients (34%) had P53 positive. There were statistically significant correlation between of Ki-67 with p53 and laterality (P<0.05). The OS for all of patients that the mean survival for them was 39.4 months and survival rate was 67.5%. Conclusions: The OS in our patients was lower than other studies. Also, there is a direct correlation between Ki67 and p53 in TNBC patients that for better conclusion it needs more studies.

Keywords:
Ki67 overall survival P53 TNBC

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, et al. Advantages of adjuvant chemotherapy for patients with TNBC at Stage II: usefulness of prognostic markers E-cadherin and Ki67, Breast Cancer Res, 13 (6), R122, 2011.
 
[2]  Zhang L, Fang C, Xu X, Li A, Cai Q, Long X. Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis, Biomed Res Int, 2015, 357485, 2015.
 
[3]  Peng Y. Potential prognostic tumor biomarkers in triple-negative breast carcinoma, Beijing Da Xue Xue Bao, 44 (5), 666-72, 2012.
 
[4]  Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer, J Clin Oncol, 23, 7212-7220, 2005.
 
[5]  Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer, Breast Cancer Res Treat, 119, 315-323, 2010.
 
[6]  Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res, 14, 1368-1376, 2008.
 
[7]  Shan M, Zhang X, Liu X, Qin Y, Liu T, Liu Y, et al. P16 and p53 play distinct roles in different subtypes of breast cancer, PLoS One, 8 (10), e76408, 2013.
 
[8]  Dang D, Peng Y. Roles of p53 and p16 in triple-negative breast cancer. 2013. 2 (6):537-44.
 
[9]  Payandeh M, Sadeghi E, Sadeghi M, Eskandar AM. Different Presentation of Treatment in Carcinomatous Meningitis of Breast Cancer: Report of 3 Cases, American Journal of Cancer Prevention, 3 (1), 4-7, 2015.
 
[10]  Payandeh M, Sadeghi M, Sadeghi E, koohian AK. Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran, American Journal of Cancer Prevention, 2 (2), 37-41, 2014.
 
[11]  Sajid MT, Ahmed M, Azhar M, Mustafa QU, Shukr I, Ahmed M, et al. Age-related frequency of triple negative breast cancer in women, J Coll Physicians Surg Pak, 24 (6), 400-3, 2014.
 
[12]  Alagizy HA, Shehata MA, Hashem TA, Abdelaziz KK, Swiha MM. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer. Hematol Oncol Stem Cell Ther. 2014.
 
[13]  Lakshmaiah KC, Das U, Suresh TM, Lokanatha D, Babu GK, Jacob LA, et al. A study of triple negative breast cancer at a tertiary cancer care center in southern India, Ann Med Health Sci Res, 4 (6), 933-7, 2014.
 
[14]  Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, Yamamura J, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients, Cancer Chemother Pharmacol, 67, 911-917, 2011.
 
[15]  Li H, Han X, Liu Y, Liu G, Dong G. Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer, Oncol Lett, 9 (1), 149-152, 2015.
 
[16]  Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis, Breast Cancer Res, 13 (2), R22, 2011.
 
[17]  Chu QD, Henderson AE, Ampil F, Li BD. Outcome for patients with triple-negative breast cancer is not dependent on race/ethnicity, Int J Breast Cancer, 2012, 764570, 2012.
 
[18]  Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer, Journal of Clinical Oncology, 24 (36), 5652-5657, 2006.
 
[19]  Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry, Cancer, 109 (9), 1721-1728, 2007.